Switzerland's universal health insurance system, LAMal, marks its 30th anniversary amid a severe affordability crisis. The system, launched in 1996, provides high-quality care and long life expectancy, but rising costs are straining its solidarity principle. Unlike tax-funded EU systems, Switzerland's population-financed model makes cost increases directly visible through monthly premiums, which reached an average of CHF423 in 2024, consuming about 7% of disposable income. A trilemma described by State Secretary Helene Budliger Artieda pits public affordability, accessibility of new treatments, and pharmaceutical profitability against each other.